Expression profile of the matricellular protein periostin in paediatric inflammatory bowel disease

Figures

• 

  Figure 1. Plasma periostin levels against disease activity. (A) Significantly lower levels in adult controls in comparison to paediatric controls (p = 0.003). (B) Higher levels during remission (combined for both CD & UC) than active disease (p = 0.002). (C) Statistically significant differences in periostin levels during remission driven by CD; remission (31,338 ± 2144) compared to active disease (25,074 ± 1108); p = 0.005. (D) Patients with UC show no significant differences during remission compared to active disease. (E) An inverse relationship between periostin levels and PCDAI scores (F) No relationship between periostin and disease activity in UC. This figure was, as also mentioned in the methods/stats section, generated through PRISM https://www.graphpad.com/scientific-software/prism/ Version 7. Abbreviations: CD- Crohn’s disease; PCDAI- paediatric Crohn’s disease activity index; PUCAI- Paediatric ulcerative colitis activity index; pIBD- paediatric inflammatory bowel disease (includes both Crohn’s disease and ulcerative colitis); UC- ulcerative colitis.

• 

  Figure 2. Immuno-fluorescence staining for periostin in colonic tissue. The figure shows representative immuno-fluorescence for periostin on the colonic tissue obtained from controls and IBD patients in the active state. Note the distinctly localised peri-cryptal rings that can be seen in CD (A, C, D) and UC (B) patients but not in the healthy control tissue (E). Interestingly, the peri-cryptal rings can be seen also in the macroscopically unaffected but histologically inflamed colonic mucosa in CD patients (D). These high intense areas appear more pronounced in CD patients compared to UC patients. Also note the very intense and diffuse staining of the epithelium and stromal tissue in the surgically resected bowel segment of a CD patient (F). Scale bar is 50 µm.

• 

  Figure 3. Periostin isoforms in the colonic tissue. The gel shows the isoforms present in tissue biopsies of CD patients (lanes 1–5), UC patient (lanes 6–7) and non-IBD controls (lanes 8–11). Lane 12 shows the negative control. Please note that there are minor fluctuations between the intensities of the different fragments that do not show any correlation between diseases CD (1–5) or UC (6–7), or controls (8–11). Fragment 1 (188 bp) is just below the 200 bp marker while fragment 4 (452 bp) is between 400 and 500 bp.

• 

  Figure 4. Sequencing of the periostin isoforms. Based on sequencing the exon usage of the four periostin isoforms isolated from the GI tissue in patients and healthy controls is shown. No alternative splicing occurs in exons 1–16 and the last exon 23 with the stop codon is also present in all variants. Fragment 1 contains exons 16, 20, 22 and 23 and is exactly 188 bp long, while fragment 2 contains additionally exon 19 and is 278 bp long. Fragment 3 additionally has exon 18 present and is 368 bp long and fragment 4 contains also exon 21 and is 452 bp long. Interestingly, we did not identify any trace of the full-length fragment that also retains exon 21 and would be expected to be 536 bp in length.

• 

  Figure 5. Network of genes for periostin. Screenshot from PathCards displaying seventeen SuperPath genes (black text) functionally connected to periostin and ten additional genes, known to be related to or influencing periostin signalling (red text). The protein nodes and the inter-connections within the retrieved network are automatically coloured for visual clarity and also to indicate the type of functional connectivity. The genes displayed in this figure are: C-X-C Motif Chemokine Receptor 4 (CXCR4); Cytohesin 1 Interacting Protein (CYTIP); Endothelial PAS Domain Protein 1 (EPAS1); Jagged Canonical Notch Ligand 1 (JAG1); Lymphoid Enhancer Binding Factor 1 (LEF1); Periostin (POSTN); Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma (PIK3CG); SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (SRC); Tenascin C (TNC); Transcription Factor 7 (TCF7); Transcription Factor 7 Like 1 (TCF7L1); Transcription Factor 7 Like 2 (TCF7L2); Vascular Cell Adhesion Molecule 1 (VCAM1); Von Hippel-Lindau Tumor Suppressor (VHL); Wnt Family Member 2 (WNT2), Rho-associated protein kinase 1 (ROCK1), Ras Homolog Family Member A (RHOA), C–C chemokine receptor type 5 (CCR5), C–C Motif Chemokine…

• 

  Figure 6. Pathophysiology of periostin. In the tissue, periostin is primarily produced by the fibroblasts and myofibroblasts. It has also been detected in tumour cells, epithelial cells and leukocytes. After engaging with the αv-integrin receptors within the cell membrane, periostin facilitates transmission of signals for cellular adhesion and activation of various immune-signalling pathways. These include the focal adhesion kinase (FAK) phosphatidylinositol 3-kinase (PI3K)/AKT, NF-κB, and RHOA and YAP/TAZ TEAD signalling pathways. These pathways further fuel inflammation and also contribute to tissue repair and remodelling as well as fibrosis and tumorigenesis. This figure was generated by TC using the software https://app.diagrams.net. (Abbreviations: TAZ, transcriptional co-activator with PDZ-binding motif; TEAD, TEA domain family member 1; YAP, Yes-associated protein1).